Abingdon Health announces the signing of an exclusive license agreement with Concepta PLC, a UK personalised healthcare company, for the use of Abingdon Health‘s lateral flow m-Health technology, AppDx®, by Concepta in the home-use human fertility tracking and pregnancy testing market.
AppDx® uses cutting-edge software to transform a smartphone into a powerful lateral flow reader, combining rapid results delivery with flexible data management. By utilising in-built smartphone camera functionality, AppDx® can read single or multiple test lines to give qualitative or quantitative test results, providing unambiguous lab-quality data for immediate viewing or secure transfer to a clinic or data hub.
AppDx® unlocks the potential for Concepta’s customers to access rapid test results, further information and connectivity with supporting services at home. Tests can be performed in any location, enabling quick decision making and allowing the patient and/or healthcare professional to follow-up for getting the right advice and easy connectivity to a healthcare team. The inclusion of intuitive workflows and in-built visual instructions enhance the patient experience and reduce the chance of user error.
Concepta and Abingdon Health will commence development work in May 2020. The partnership follows the recent outsourcing agreement with Abingdon for the manufacture of myLotus® and marks Concepta’s future strategic intention to provide a complementary technology to the Company’s existing portfolio, and a platform that responds to evolving market needs as consumer connectivity in the Femtech space continues to build momentum.
This is an exciting period for AppDx®. This new agreement with Concepta comes weeks after Abingdon Health signed an agreement with US-based DCN Diagnostics. The commercial partnership sees the Californian lateral flow developer provide Abingdon Health’s proprietary AppDx® m-Health technology to its customer base.
Chris Yates, Chief Executive Officer of Abingdon Health, commented:
“Selecting our first consumer application for AppDx has been an important step for us, and in Concepta we have an ambitious partner that is very much looking ahead within the Femtech space. Abingdon’s leading-edge AppDx technology is perfectly suited to enhance Concepta’s digital health strategy and support this highly engaged user group through their fertility journeys.”
Penny McCormick, Chief Executive Officer of Concepta PLC, commented:
“Our AppDx license provides us with a great opportunity to offer enhanced customer value and experience and allows us to help our patients with personalised testing and information in an even more convenient way that is complementary to our portfolio. In Abingdon, we are partnering with a strong and highly experienced development partner who leads in connected technology. Their credibility and depth of knowledge in the rapid diagnostic and software environment makes them a great partner for Concepta. We look forward to collaborating with them on this exciting platform.”
About Abingdon Health (www.abingdonhealth.com)
Abingdon is a UK-based developer and manufacturer of lateral flow tests and smartphone reader solutions. Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing. Abingdon is headquartered in York, England with facilities in Birmingham and York.
About Concepta PLC (www.conceptaplc.com)
Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman’s chances of naturally getting pregnant and to provide insight to unexplained infertility.